Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain
The respiratory syncytial virus (RSV) fusion protein (F) facilitates virus-cell membrane fusion, which is critical for viral entry, and cell-cell fusion. In contrast to many type I fusion proteins, RSV F must be proteolytically cleaved at two distinct sites to be fusogenic. Cleavage at both sites results in the release of a 27 amino-acid fragment, termed Pep27. We examined proteolytic processing and the role of Pep27 for RSV F from both RSV A2 and RSV B9320 laboratory-adapted strains, allowing important comparisons between A and B clade F proteins. F from both clades was cleaved at both sites, and pulse-chase analysis indicated that cleavage at both sites occurs early after synthesis, most likely within the secretory pathway. Mutation of either site to alter the furin recognition motif blocked cell-cell fusion activity. To assess the role of Pep27 in F processing and expression, we deleted the Pep27 fragment, but preserved the cleavage sites. Deletion of Pep27 reduced F surface expression and cell-cell fusion. Two conserved N-linked glycosylation sites within Pep 27 are present in both the RSV A2 and RSV B9320 F. Randomization of the Pep27 sequence, while conserving the two N-liked glycosylation sites, did not significantly change surface expression, and only modestly reduced cell-cell fusion. However, the disruption of either Pep27 glycosylation site reduced cell-cell fusion. This work clarifies the timing of RSV F proteolytic cleavage and offers insight into the crucial role the N-linked glycosylation sites within Pep27 play in the biological function of F.
Authors
- Chelsea T. Barrett
- Rebecca Dutch (ORCID: https://orcid.org/0000-0002-5220-8247)
- Kearstin Edmonds
- Carole L. Moncman
- Hadley E. Neal (ORCID: https://orcid.org/0000-0001-8433-593X)
Institutions
- University of Kentucky (US)
Publication Details
- Journal
- Journal of Virology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1128/jvi.01639-24
- Citations
- 5
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- AstraZeneca
- Novavax
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases